News - Gleevec

Filter

Current filters:

Gleevec

Popular Filters

CML drug revenue in Japan to grow, despite global decline, says GlobalData

21-05-2013

Bucking a global trend of falling revenues, weak penetration of generic drugs and an increasing patient…

Asia-PacificBristol-Myers SquibbGleevecMarkets & MarketingNovartisOncologyPatentsPharmaceuticalSprycel

Small-molecule cancer drug revenues will reach $32.7 billion in 2016, says Visiongain

09-01-2013

The small-molecule targeted cancer therapy revenues will reach a value of $32.7 billion worldwide in…

BiotechnologyGleevecGlivecGlobalMarkets & MarketingNovartisOncologyPharmaceutical

FDA approves Teva's Synribo for CML; Novartis plans for Tasigna switch

29-10-2012

The US Food and Drug Administration on Friday approved Israel-headquartered Teva Pharmaceutical Industries'…

GleevecNorth AmericaNovartisOncologyPatentsPharmaceuticalRegulationResearchSynriboTasignaTeva Pharmaceutical Industries

Overview of Novartis' patent losses from GlobalData

11-10-2012

Swiss drug major Novartis (NOVN: VX) is the latest victim of patent protection loss, note analysts at…

DiovanFemaraFinancialGleevecNovartisPatentsPharmaceuticalReclastZometa

Novartis Indian Supreme Court hearings again re-scheduled

09-07-2012

Humanitarian aid agency Medecins Sans Frontieres said on Friday it has learnt that final arguments in…

Asia-PacificGenericsGleevecGlivecLegalNovartisPatentsPharmaceutical

More news for ASH meeting

13-12-2011

In continuing news from the 53rd annual meeting of the American Society of Hematology (ASH) in San Diego,…

Avila TherapeuticsGleevecNovartisOncologypacritinibPharmaceuticalResearchS*BIOTasigna

Novartis' imatinib patent battle resumes in Indian Supreme Court

15-08-2011

The controversial Novartis case in which the Swiss major Novartis (NOVN: VX) challenged the manner in…

Asia-PacificGleevecGlivecNovartisOncologyPatentsPharmaceutical

Back to top